Latest News
Gilead Presents Data from Nonalcoholic Steatohepatitis Development Program for Advanced Fibrosis
13 November 2018 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has presented new data from the company's clinical development programme for advanced fibrosis due to nonalcoholic steatohepatitis, the company said.
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting 2018
13 November 2018 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has presented results from studies investigating Epclusa (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus infected patients with severe...
Alnylam Presents Updated Phase 1/2 Open-Label Extension Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
13 November 2018 - - US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading, announced TODAY that the company presented updated results from the ongoing Phase 1/2 open-label extension study of givosiran, an ...
Alpine Immune Sciences Advances Oncology Programmes with New ALPN-202 Preclinical Data
13 November 2018 - - US-based immunotherapy company Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has advanced its oncology programme, the company said.

Following promising preclinical data presented TODAY at the Society for Immunotherapy ...
Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
13 November 2018 - - US-based biotechnology company Obsidian Therapeutics, Inc has presented preclinical data demonstrating fine-tuned regulation of cytokine production and CAR-T function using Destabilizing Domains paired with FDA-approved small mol...